Safety and immunogenicity of Shigella sonnei-CRM₉ and Shigella flexneri type 2a-rEPA_succ conjugate vaccines in one- to four-year-old children

Keyphrases

• Shigella Sonnei 100%
• Shigella Flexneri 100%
• Immunogenicity 100%
• Conjugate Vaccine 100%
• Four-year-old children 100%
• Shigella 50%
• Second Dose 50%
• 4-year-olds 50%
• First Injection 50%
• Immunogenic 33%
• Older children 33%
• Fever 33%
• Immunization 33%
• 4-fold 33%
• Israel 16%
• Shigellosis 16%
• Carrier Protein 16%
• Shigella Flexneri 2a 16%
• O-polysaccharide 16%
• Pseudomonas Aeruginosa Exotoxin A 16%
• Diphtheria Toxin 16%
• Lipopolysaccharide 16%
• Vaccinees 16%
• Enzyme-linked Immunosorbent Assay (ELISA) 16%
• Age Groups 16%
• Diphtheria 16%
• Adult Volunteers 16%
• Liver Function Tests 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Shigella flexneri 100%
• Conjugate Vaccine 100%
• Immunogenicity 100%
• Shigella sonnei 100%
• Shigella 75%
• Shigellosis 25%
• Diphtheria Toxin 25%
• Lipopolysaccharide 25%
• Polysaccharide 25%
• Enzyme-Linked Immunosorbent Assay 25%
• Diphtheria 25%
• Pseudomonas aeruginosa Exotoxin A 25%